Shenzhen HeatShock Biotech

Shenzhen HeatShock Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies based on the heat shock protein gp96 (HSP gp96) platform. Founded by Dr. Songdong Meng from the Chinese Academy of Sciences, the company leverages the unique molecular chaperone and immune-modulating properties of gp96 to treat neurodegenerative diseases, cancers, and chronic viral infections. Their lead program is a high-dose gp96 therapy for Amyotrophic Lateral Sclerosis (ALS), which has demonstrated safety and preliminary efficacy in first-in-human clinical trials by restoring immune homeostasis through the activation of regulatory T cells (Tregs). The company is also advancing pipeline candidates for various oncology indications and chronic hepatitis B.